Abstract: A gas turbine engine component includes a gas turbine engine component body formed of a ceramic matrix composite material having at least one fastener integrally formed with the gas turbine engine component body as a single-piece structure. The gas turbine engine component body initially comprises a rigidized preform structure formed from a polymer based material. The at least one fastener connects the gas turbine engine component body to an engine support structure.

Abstract: The invention relates to a composition for inorganic binders, comprising at least one ketone-formaldehyde condensation product on the basis of a cyclic ketone and at least one anionic or nonionic surfactant and/or a thickener, and also to building material mixtures which comprise this composition, and to the use of the composition. The compositions improve the applications properties of the binder formulations.

Abstract: An article including carbon-carbon composite substrate may be treated with an antioxidant coating prior to use in an oxidizing environment. The antioxidant coating may be configured to reduce oxidation at an external surface of the C—C composition and reduce ingress of oxidants into pores or other open passages defined by the C—C composite substrate to avoid internal oxidation. An example article includes a C—C composite substrate, a bond coat, and an antioxidant coating. The C—C composite substrate defines a friction surface and a non-friction surface. The bond coat is disposed on the non-friction surface. The antioxidant coating may be disposed on at least a portion of the bond coat. The antioxidant coating may include ytterbium disilicate and a sintering aid.

Abstract: The present disclosure is related to a fertilizer (inorganic/organic/natural/synthetic) enriched with acclimatized (preferably halotolerant) effective microorganisms (AEM) and optionally with an organic emulsion (OE). The present disclosure provides a bioaugmented fertilizer enriched with AEM and optionally OE. Provide product (fertilizer) specific AEM, and method for producing such fertilizers. Fertilizer enriched with AEM, OMP, and OE renders it an Integrated Plant Nutrient Management (IPNM) principles based product (fertilizer). This makes it superior in performance over conventional fertilizers (inorganic/organic/natural/synthetic) due to better nutrient use efficiency.

Abstract: A new chromium-containing fluorination catalyst is described. The catalyst comprises an amount of zinc that promotes activity and from 0.1 to 8.0% by weight of the chromium in the catalyst based on the total weight of the chromium is present as chromium (VI). The use of the zinc-promoted, chromium-containing catalyst in a fluorination process in which a hydrocarbon or halogenated hydrocarbon is reacted with hydrogen fluoride in the vapour-phase at elevated temperatures is also described.

Abstract: Methods for determining ethylene concentration in an ethylene oligomerization reactor using an ultrasonic flow meter are described, and these methods are integrated into ethylene oligomerization processes and related oligomerization reactor systems.

Abstract: A polynitroso compound including a monocyclic core or a polycyclic core attached with two or more of terminal nitroso groups thereon, such as Formula (A) to Formula (D), in particular, Formula (VII). A method for preparing the polynitroso compound of the present invention. An energy storage device with a cathode including the polynitroso compound of the present invention. Also an electrode material for an energy storage device including a polynitroso compound having a monocyclic core with at least one terminal nitroso group, such as Formula (A) to Formula (D), in particular, Formula (VII).

Abstract: The invention relates to bis(aniline) compounds containing multiple arylethynyl, alkylethynyl, ethynyl groups or their combinations, processes of making such compounds and materials comprising such compounds. Such, bis(aniline) compounds preferably comprise multiple phenylethynyl (PE) groups, i.e. 2-4 PE moieties. Such compounds are useful monomers for the preparation of polyimides, polyamides and poly(amide-imides) whose post-fabrication crosslinking chemistry (i.e. reaction temperature) can be controlled by the number of PE per repeat unit as well as finding utility in thermosetting matrix resins, 3D printable resins, and as high-carbon-content precursors to carbon-carbon composites.

Abstract: Antidegradant composition comprising a first compound of Formula I: and a second antidegradant that is not the compound of Formula I; and rubber composition comprising the antidegradant composition. The rubber composition has good resistance to appearance discoloration while maintaining the mechanical and anti-aging properties, thus, are suitable for making the entire tire or as part of the rubber matrix.

Abstract: The present invention relates to a synthesis method of hydroxybenzylamine, belonging to the technical field of organic synthesis. The principle of the method is a demethylation reaction of methoxybenzylamine in the presence of hydrobromic acid. The present invention has the characteristics that methoxybenzylamine and hydrobromic acid are distilled at reflux to remove redundant water to improve a reaction temperature and increase the concentration of hydrobromic acid in a reaction mixture, thereby enhancing the demethylation of hydrobromic acid on methoxybenzylamine and then shortening a reaction time and increasing a conversion rate; when generation of a methyl bromide gas is not observed, distillation is continued, excess hydrobromic acid is recycled to further improve the reaction temperature and increase the conversion rate and meanwhile reduce the consumption of raw material hydrobromic acid and decrease the processing capacity of the subsequent steps and the consumption of raw material sodium hydroxide.

Abstract: The present disclosure relates to PEG-lipids, cationic and/or ionizable lipids and nucleic acid-lipid particle compositions comprising the same. The present disclosure also relates to methods of making, using and delivering the described lipids and lipid-containing particles.

Abstract: A process for producing methanol, wherein a make-up gas stream from a reformer unit is admixed with a hydrogen-containing stream from a hydrogen recovery stage to obtain a hydrogen-rich synthesis gas, which is combined with a residual gas stream and the combined stream is passed through a bed of a methanol synthesis catalyst at elevated pressure and elevated temperature to obtain a product stream comprising methanol and the residual gas stream and wherein the product stream is cooled to remove methanol from the residual gas stream. Wherein a portion of the residual gas stream is removed as a purge gas stream and a portion of the hydrogen-rich synthesis gas stream is removed and combined with the purge gas stream to obtain a mixed synthesis gas stream and the mixed synthesis gas stream is sent to the hydrogen recovery stage to produce the hydrogen-containing stream.

Abstract: Modular dendrimers with cationic groups and lipophilic groups are provided herein. In some aspects, the dendrimers provided herein may be formulated in compositions which contain a nucleic acid and one or more helper excipients. In some aspects, these compositions may also be used to treat diseases or disorders with a therapeutic nucleic acid.

Abstract: An object of the present invention is to provide a method for producing m-dialkylbenzaldehyde by using a reaction starting material containing 1,4-dialkylbenzene. The method for producing m-dialkylbenzaldehyde represented by formula (3), comprising a step of allowing carbon monoxide to react on a reaction starting material containing 1,4-dialkylbenzene represented by formula (1) in the presence of a Bronsted acid and a Lewis acid, wherein the reaction starting material is 1,4-dialkylbenzene represented by formula (1), or a mixture of 1,4-dialkylbenzene represented by formula (1) and 1,3-dialkylbenzene represented by formula (2), containing 10 mol % or more of the 1,4-dialkylbenzene represented by formula (1), wherein in formulae (1) to (3), R1 represents a methyl group or an ethyl group, and R2 represents a chain or cyclic alkyl group having 3 or more and 6 or less carbon atoms that has a tertiary carbon at the benzyl position.

Abstract: A method for the isomerization of alpha-olefins to the corresponding internal olefins uses a heterogenous catalyst containing silicon-aluminum mixed oxide in a continuous fixed-bed operation mode.

Abstract: A complex salt formed from a compound of formula (I) and an alkaloid, a preparation method therefor and use thereof are provided. In particular, a complex salt formed from rupestonic acid and matrine, oxymatrine, sophocarpine and sophoridine, or a composition thereof, has potential efficacy in treating a tumor/cancer or preparing related medicaments.

Abstract: Disclosed are chelating co-polymer compositions that are soluble in aqueous media and chelate essential metals, methods of preparation and uses thereof. The chelating compositions are comprised of two or more different monomers, at least one of which possesses metal binding or metal chelating activity. The chelating compositions are synthesized by reversible addition-fragmentation transfer (RAFT) polymerization with the aid of a suitable RAFT-mediating agent. Also described are chelating compositions that comprise hydroxypyridinone chelating groups. The ability of the chelating compositions to bind metals affects the activity of a living cells and organisms, which require the metals for cellular functions.

Abstract: The disclosure provides processes for synthesizing compounds for use as CFTR modulators.

Abstract: The present invention relates to a process for preparation of strobilurin compound, azoxystrobin and its intermediates using a catalyst selected from 1,8-Diazabicyclo[5.4.0]undec-7-ene or 1,5-Diazabicyclo[4.3.0]non-5-ene, salts thereof, or derivatives thereof.

Abstract: The present disclosure provides compounds represented by Formula I: and pharmaceutically acceptable salts, solvates, e.g., hydrates, and prodrugs thereof, wherein X and n are as defined as set forth in the specification. The present disclosure also provides compounds of Formula I for use to treat diseases and conditions, e.g., cancer, wherein inhibition of HDAC provides a benefit.

Abstract: Provided are a compound III serving as an LSD1 inhibitor and a crystal form thereof, as well as use of the compound and the crystal form thereof in preparation of a medicament for treating an LSD1 related disease.

Abstract: The invention relates to 1,5-benzothiazepine derivatives of formula (I). These compounds are bile acid modulators having apical sodium-dependent bile acid transporter (ASBT) and/or liver bile acid transport (LBAT) inhibitory activity. The invention also relates to pharmaceutical compositions comprising these compounds and to the use of these compounds in the treatment of cardiovascular diseases, fatty acid metabolism and glucose utilization disorders, gastrointestinal diseases and liver diseases.

Abstract: Disclosed herein are methods for synthesizing useful intermediates and/or products from 1,2,5,6-hexanetetrol (HTO), which itself can be derived from a sugar. In an aspect, a process is provided for production of THFDCA from 1,2,5,6-hexanetetrol (HTO). The process comprises the steps of (a) ring closing to form a ring compound and (b) oxidizing using a catalyst comprising platinum and bismuth to form an acid mixture. Step (a) may be performed before or after step (b).

Abstract: Disclosed are methods for performing dynamic nuclear polarization using the polarizing agents described herein. In general, the methods involve (a) providing a frozen sample in a magnetic field, wherein the frozen sample includes a polarizing agent described herein and an analyte with at least one spin half nucleus; (b) polarizing the at least one spin half nucleus of the analyte by irradiating the frozen sample with radiation having a frequency that excites electron spin transitions in the polarizing agent; (c) optionally melting the sample to produce a molten sample; and (d) detecting nuclear spin transitions in the at least one spin half nucleus of the analyte in the frozen or molten sample. In certain embodiments, the polarizing agents can be peptide-based. In these embodiments, the polarizing agents can be readily prepared by solid-phase peptide synthesis.

Abstract: This invention relates to compounds that are agonists of the muscarinic M1 receptor and/or M4 receptor and which are useful in the treatment of muscarinic M1/M4 receptor mediated diseases. Also provided are pharmaceutical compositions containing the compounds and the therapeutic uses of the compounds. Compounds include those according to formula 1 or a salt thereof, wherein q, r, s, Q, R1, R2?, R2?, R3 and R4 are as defined herein.

Abstract: The present disclosure provides an herbicidal compound according to Formula I, which is a five-membered ring-substituted pyridazinol compound, as well as derivatives of the compound, an herbicidal composition comprising the compound, preparation methods thereof, and applications thereof.

Abstract: Disclosed herein are plinabulin polymorphs, compositions, their use and preparation as therapeutic agents. In particular, some embodiments relate to plinabulin monohydrate in a crystalline form.

Abstract: Disclosed herein are compounds, compositions, and methods for selecting targeting ?2AR receptors. The compounds, compositions, and methods may be used in the treatment of obstructive lung diseases.

Abstract: Provided is a novel class of orally and/or topically available, selective and potent JAK inhibitors as safe and effective therapeutics against various diseases and disorders. Also provided is pharmaceutical composition of these compounds and methods of a their preparation and use thereof.

Abstract: Anti-angiogenic treatments and compounds for use in anti-angiogenic treatments, particularly of conditions associated with abnormal angiogenesis or abnormal over-production of pro-angiogenic VEGFxxx isoforms in or on the eye are described.

Abstract: The present invention aims to provide a compound that may be useful for the prophylaxis or treatment of constipation and the like. The present invention provides a compound represented by the following formula (I): wherein each symbol is as described in the specification, or a salt thereof.

Abstract: The present invention relates to compounds of Formula I as defined herein, and salts and solvates thereof. (I) The present invention also relates to pharmaceutical compositions comprising compounds of Formula (I), and to compounds of Formula (I) for use in the treatment of proliferative disorders, such as cancer, as well as other diseases or conditions in which inhibition of a RAS-effector protein-protein interaction is implicated.

Abstract: The present application provides compounds that may be used as a glucagon-like peptide-1 receptors (GLP-1R) agonist, or pharmaceutically acceptable salts thereof. Also provided are pharmaceutical compositions containing such compounds, or pharmaceutically acceptable salts thereof. Methods of preparing these compounds and compositions, and methods of using these compounds and compositions to treat or prevent a disease or a condition mediated by GLP-1R, are also provided.

Abstract: The invention relates to a new family of compounds of the type 2,3-dihydroquinazolin-4(1H)-one and the use thereof as inhibitors of the toxic effects of intracellular-acting toxins, such as ricin, Shiga toxins or the cholera toxin, using retrograde transport to intoxicate the cells, or viruses or bacteria using retrograde and/or syntaxin 5-dependent transport to infect the cells, specifically viruses or bacteria entering into the cells by means of endocytosis, or intracellular parasites.

Abstract: The present invention relates to compounds that are inhibitors of the orexin-1 receptor. The compounds have the structural formula I defined herein. The present invention also relates to processes for the preparation of these compounds, to pharmaceutical compositions comprising them, and to their use in the treatment of diseases or disorders associated with orexin-1 receptor activity.

Abstract: The present invention provides novel pyrazolopyridine-diamides of Formula (I), wherein, the definition of W1, W2, A1, A2, A3, B1, B2, D, Z1, E, R1, R2, R3, R4, m and n is as described in the description. The present invention also relates to the composition, combination, use and method of application of the compounds of Formula (I).

Abstract: Provided herein are substituted imidazo[1,2-a]pyridin-2-ylamine compounds, for example, of formula (A), and pharmaceutical compositions thereof; and methods of their use for treating, preventing, or ameliorating one or more symptoms of a Janus kinase-mediated disease.

Abstract: Improving the solubility of an organic compound. A cocrystal of (1) 6-ethyl-N-[1-(hydroxyacetyl)piperidin-4-yl]-1-methyl-4-oxo-5-(2-oxo-2-phenylethyl)-3-(2,2,2-trifluoroethoxy)-4,5-dihydro-1H-pyrrolo[3,2-c]pyridine-2-carboxamide and (2) L-malic acid or L-tartaric acid.

Abstract: The present invention provides compounds of Formula (I): wherein all of the variables are as defined herein. These compounds are modulators of NLRP3, which may be used as medicaments for the treatment of proliferative disorders, such as cancer in a subject (e.g., a human).

Abstract: Imidazo[4,5-c]quinoline compounds having a substituent that is attached at the N?1 position by a branched group, single enantiomers of the compounds, pharmaceutical compositions containing the compounds, and methods of making the compounds are disclosed. Methods of use of the compounds as immune response modifiers, for inducing cytokine biosynthesis in humans and animals, and in the treatment of diseases including infectious and neoplastic diseases are also disclosed.

Abstract: The present disclosure relates to compounds according to Formula I (I) or a pharmaceutically acceptable salt and/or solvate thereof, as well as compositions including such compounds and uses thereof, where R1 is an unsubstituted C1-C12 alkyl; and R2, R3, and R4 are each independently H or —C(O)—(unsubstituted C1-C12 alkyl). Among other things, the present disclosure evidences that the significant upregulation of CD20 by the inhibition of a-mannosidase enzymes by compounds of the present technology potentiates the activity of anti-CD20 mAbs and importantly sensitize cell lines that are resistant to the action of these antibodies.

Abstract: The invention provides a novel class of therapeutics that are safe and effective inhibitors of Janus kinase 1 and pharmaceutical composition and methods of preparation and use thereof in the treatment of various diseases and disorders (e.g., inflammatory diseases, immune-mediated diseases or cancer).

Abstract: The present invention relates to salt forms of the Fibroblast Growth Factor Receptors (FGFR) inhibitor 3-(2,6-difluoro-3,5-dimethoxyphenyl)-1-ethyl-8-(morpholin-4-ylmethyl)-1,3,4,7-tetrahydro-2H-pyrrolo[3?,2?:5,6]pyrido[4,3-d]pyrimidin-2-one, including methods of preparation thereof, where the compound is useful in the treatment of FGFR mediated diseases such as cancer.

Abstract: Novel pyrazolo[4,3-c][1,6]naphthyridine compounds, a method of synthesizing said compounds, a pharmaceutical composition comprising said compounds and a suitable carrier, and a method of using the compounds. The pyrazolo[4,3-c][1,6]naphthyridine compounds, identified as CK2 inhibitors, are useful as anticancer and/or antitumor agents, and as agents for treating other kinase-associated conditions including inflammation, pain, and certain immunological disorders, and other types of diseases such as diabetes, viral infection, neurodegenerative diseases.

Abstract: The present invention provides the compound represented by the following formula (I): wherein a moiety represented by formula: is or the like. The symbols are defined in the specification. The compounds of the present invention have MGAT2 inhibitory activity, and are useful as a medicine for treatment of MGAT2-associated diseases including obesity, metabolic syndrome, hyperlipidemia, hypertriglyceridemia, hyper-VLDL-triglyceridemia, hyperfattyacidemia, diabetes mellitus, and arteriosclerosis.

Abstract: The present disclosure relates, in general, to improved processes for the preparation of 4-{8-amino-3-[(2S)-1-(but-2-ynoyl)pyrrolidin-2-yl]imidazo[1,5-a]pyrazin-1-yl}-N-(pyridin-2-yl)-benzamide, particularly large-scale processes for manufacturing 4-{8-amino-3-[(2S)-1-(but-2-ynoyl)pyrrolidin-2-yl]imidazo[1,5-a]pyrazin-1-yl}-N-(pyridin-2-yl)benzamide and intermediates used in such processes.

Abstract: Described herein are compounds, pharmaceutical compositions and methods of using these compounds and pharmaceutical compositions for treating and/or preventing conditions such as amyotrophic lateral sclerosis. These compounds and pharmaceutical compositions are also useful as antivirals and antimicrobial agents.

Abstract: The present application provides processes for preparing (R)-4-(3-((S)-1-(4-amino-3-methyl-1H-pyrazolo[3,4-d]pyrimidin-1-yl)ethyl)-5-chloro-2-ethoxy-6-fluorophenyl)pyrrolidin-2-one, which is useful as an inhibitor phosphoinositide 3-kinase-delta (PI3K?), as well as a salt form and intermediates related thereto.

Abstract: The present application relates to novel compounds of formula (I) to their utility in treating and/or preventing clinical conditions including cardiovascular diseases (CVD), to methods for their therapeutic use, to pharmaceutical compositions containing them and to processes for preparing such compounds.

Abstract: The present application discloses compounds having the following formula: or pharmaceutically acceptable salts thereof, wherein R1, R2, R3, R4 and R5 are defined in the specification, as well as methods of making and using the compounds disclosed herein for treating or ameliorating an IL-17 mediated syndrome, disorder and/or disease.